Partner
Cora handles cases involving a variety of technologies, with an emphasis on the biotechnology, pharmaceutical, and life sciences industries, including Hatch-Waxman and biologics cases. She has represented clients in cases involving small and large molecules, medical devices, human therapeutic antibodies, gene therapies, drug delivery systems, soybean plants, and engineered microorganisms, to name a few. Her experience spans all aspects of patent litigation, including pre-suit diligence, case strategy, fact and expert discovery, dispositive motions and briefs, pretrial and trial submissions, preparing and examining witnesses at trial, and presenting argument before trial and appellate courts.
In addition to her litigation work, Cora assists clients in portfolio counseling matters and proceedings before the USPTO. She has been recognized as a Rising Star and an IP Star by Managing Intellectual Property magazine and was named to the Best Lawyers 2021 One to Watch list. Cora also devotes significant time to pro bono work, particularly the representation of veterans in cases before the Federal Circuit, the U.S. Court of Appeals for Veterans Claims, and the U.S. Court of Federal Claims.
Cora serves as the hiring partner for Finnegan's Washington, D.C. office.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Abbott Biotechnology Ltd. v. Centocor Ortho Biotech Inc.
4:09-cv-40089, D. Mass., Judge Saylor
Abbvie Inc. v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust
1:11-cv-02541; 1:13-cv-01358, S.D.N.Y., Judge Crotty
13-1545; 14-1672, Fed. Cir., Judges Chen, Dyk, Wallach, Taranto
Representing Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.
2:17-cv-10230, D.N.J., Judges Mannion, Salas
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
Represented Ajinomoto in the Southern District of New York in litigation involving patents related to genetically modified organisms and the use thereof to make commercial quantities of tryptophan. This representation follows successful representation of Ajinomoto in related IPR proceedings, ITC investigation, and subsequent Federal Circuit appeal.
1:16-cv-03498, S.D.N.Y., Judges Gorenstein, Vyskocil
337-TA-1005, ITC, Judges Bullock, Essex
18-1590, -1629, Fed. Cir., Judges Dyk, Moore, Taranto
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
Counsel for American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client.
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
Event
2024 AIPLA Women in IP DC Community Service Event 2024 AIPLA Women in IP DC Community Service Event
January 23, 2024
Washington
Event
Patent Infringement, Safe Harbor, and Drug Development: Navigating the Uncertain Boundaries, Recent Court Treatment Patent Infringement, Safe Harbor, and Drug Development: Navigating the Uncertain Boundaries, Recent Court Treatment
November 30 2023
Webinar
Podcasts
October 2023 - Last Month at the Federal Circuit Podcast Series October 2023 - Last Month at the Federal Circuit Podcast Series
November 2, 2023
Federal Circuit IP Blog
Podcast Series: Last Month at the Federal Circuit - October 2023 Podcast Series: Last Month at the Federal Circuit - October 2023
November 2, 2023
Press Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
Twenty Finnegan Attorneys Recognized by Best Lawyers Twenty Finnegan Attorneys Recognized by Best Lawyers
August 20, 2021
U.S. News—Best LawyersPress Release
38 Finnegan Attorneys Named Managing Intellectual Property IP Stars; Firm Maintains Tier 1 Rankings 38 Finnegan Attorneys Named Managing Intellectual Property IP Stars; Firm Maintains Tier 1 Rankings
July 8, 2021
Managing Intellectual PropertyCommentary
5 Patent Cases to Watch in the Second Half of 2021 5 Patent Cases to Watch in the Second Half of 2021
July 7, 2021
Law360Commentary
Inventorship Rulings Show Fed. Cir.'s Sympathy for a Good Story Inventorship Rulings Show Fed. Cir.'s Sympathy for a Good Story
June 18, 2021
Bloomberg LawAnnouncement
Best Lawyers Recognizes 21 Finnegan Attorneys Best Lawyers Recognizes 21 Finnegan Attorneys
August 28, 2020
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.